2021 SNO Abstract #: CTNI-03

Extended Benefits in Patients With Recurrent High-Grade Glioma That Continuously Receive Toca FC After Toca 511 Treatment

Tobias Walbert¹, Denise Damek², Nina Martinez³, David Piccioni⁴, Samuel Singer⁵, Timothy Cloughesy⁶

¹Henry Ford Health System and Wayne State University of California San Diego, La Jolla, CA; ⁵Hackensack University, Hackensack, NJ; ⁶University of California Los Angeles, Los Angeles, CA

Compassionate Use Program, Patient History

Total FC

Treatment

52

44 (with a 4

mo gap)

39

35

29

89

duration

(mo)

Toca FC dose

starting date

(220mg/kg/day)

2017-01-13

2017-04-18;

2020-12-29

2018-07-31

2018-06-18

2018-12-18

2013-12-03

BACKGROUND

Toca 511 and Toca FC: Mechanism

•Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating vector (RRV) constructed with a codon-optimized yeast cytosine deaminase (CD) gene.

•Toca 511 infects cancer cells, and stably delivers CD gene whose protein product converts courses of the prodrug Toca FC (5-fluorocytosine) into 5-fluorouracil (5-FU).

Phase 2/3 Trial Design, Setting, and Participants (Toca 511-15-01)

- Randomized, open-label trial in 58 centers comparing post-tumor resection treatment with Toca 511 followed by Toca FC vs a defined single choice of approved (SOC) therapies conducted from November 30, 2015, to December 20, 2019
- One of the largest trials in rHGG (403 patients enrolled) using viral mediated therapy
- Patients received tumor resection for first or second rGBM or rAA
- Experimental arm:

PI-Site of Patient Gender Current

Μ

Μ

Cloughesy-UCLA

Martinez -

Singer –

Hackensack

Damek - Univ.

Walbert – Henry

Walbert – Henry

University

Colorado

Ford

Ford

Jefferson Health

- Toca 511: Up to 4 mL (1.3 x 10⁹ TU)
- Toca FC: 220 mg/kg/day


age

50

41

38

33



Phase 2/3 Trial Results (Toca 511-15-01) (1)

• Among patients who underwent tumor resection for first or second rGBM or rAA, administration of Toca 511 and Toca FC, compared with SOC, did not improve overall survival or other efficacy end points • The rates of adverse events were similar in the Toca 511/FC group and the SOC control group

SD

SD

SD

SD

SD

CR

Pathology

MGMT

Unmethylated MGMT

IDH1 mutant with methylated

amplification, duplication exons

Methylated MGMT, EGFR

Methylated MGMT, IDH wt,

mMGMT; EGFR viii negative,

1p/19 LOH: Negative for allelic

1p/19q intact; 1DH1-R132H(+);

GBM, IDH wt, MIB 50%;

Ki-67/MIB-1 up to 10%.

18-26, EGFRvIII wt

EGFRvIII wt

loss

Type of tumor (when | CR or PR

started Toca 5 study) SD or PD

rAA to the right

frontal lobe

rGBM left anterior

temporal lobe

rGBM, right partial

Progression of GBM

GBM


AA, WHO 3, Toca 11

Conclusions

 Duration of extended treatment with Toca FC ranges 29 months - 7 years and 5 months (average 49.2 months)

•Six patients who are still on active treatment with Toca FC have either stable disease or complete response

•Toca FC is well tolerated in these patients, typical side effects include diarrhea



• Five clinical phase 1 studies and a clinical phase 2/3 study tested Toca 511 in combination with Toca FC in patients undergoing planned resection for recurrent High Grade Glioma (rHGG), glioblastoma (rGBM) or anaplastic astrocytoma (rAA).

• Control arm: Investigator choice single agent bevacizumab, lomustine, or temozolomide

Date of

Diagnosis

2015-11

2012-11

2017-10

2017-07

2018-04

2013-02

Initial

Date of

2016-11

2016-01

2018-05

2018-04

2018-10

Toca 511

2016-08-12

2017-01-17

2018-06-11

2018-05-10

2018-11

2013-10

date

Recurrence injection

 Some patients with rGBM or rAA appear to benefit from extended TocaFC treatment after Toca 511

• Further analysis is needed to explore factors that might predict prolonged responses in select patients

Acknowledgement

Acknowledgment: Toca 511 and Toca FC are now

•The last trial was completed in 2019. While the Phase 2/3 study did not meet the primary objective:

 Long term disease control with continued treatment with Toca 5FC via compassionate use:

- Seven patients total
- •3 men, 4 women
- Five with rGBM
- •Two with rAA

•The compassionate use program is conducted under expanded access INDs for individual patients.

•Subjects who have received Toca 511 in a prior study and, in the opinion of the PI, were benefitting from treatment with Toca FC were eligible for enrollment.

											une
ccioni – UCSD	Μ	Decease	2014-01	2014-10	2014-10;	2014-11 - 2019-	63	Patient started with	1 st	NGS: BTG1 E50Dfs*30; TBM low	Bio
		d at 76			2019-04	02;		Toca 11 study, GBM	injection-	4.2mut/Mb	
						2019-05 - 2020-		and then Toca 5 study	CR; 2 nd		cor
						05		· ·	injection-PR		FC
									-		

Compassionate Use Program, Patient Case Studies

SINGER - Hackensack

A 57-year-old woman presented with confusion, and a right parieto-occipital tumor was resected in 11/2017, revealing GBM, MGMT methylated, IDH wildtype.

She was treated with radiation (60 Gy) and concurrent temozolomide, complicated by pancytopenia, limiting adjuvant temozolomide. She was treated with pembrolizumab for 2 cycles, followed by progressive enhancement, resected in 6/2018 on treatment arm of protocol Toca511-15, with pathology confirming recurrent tumor.

She initiated Toca FC per protocol, without enhancement on baseline MRI. She has completed 28 cycles to date, well tolerated. Scans initially showed increased enhancement which subsided with time.

CLOUGHESY - UCLA

A 49-year-old woman was initially diagnosed with anaplastic astrocytoma, WHO III, unmethylated MGMT in 11/2015. The patient received DC Vax therapy followed by proton radiation from 3/21/2016 to 5/5/2016. In addition to 3 doses of DC Vax, she received 3 treatments with experimental Gamma Delta treatment, all in 2016. After her MRI showed disease progression, the patient underwent repeat surgery as part of the phase 2/3 randomized protocol Toca 511-15-01 on 12/8/2016. The patient was randomized onto the TOCA-511 arm and had a gross total resection. She initiated Toca FC per protocol. The patient has started Cycle 33 on 7/19/2021.

nder development by Denovo iopharma LLC. Denovo ontinuously provides the Toca C drug supply for patients in the compassionate use


programs.


Bibliography

• (1) Cloughesy TF, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018;20(10):1383–1392

• (2) Cloughesy TF, et al. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma. A Randomized Clinical Trial. JAMA Oncol. 2020;6(12):1939-1946







Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission of the authors